Abstract
The aim of the present investigation was to prepare and evaluate novel bioadhesive vaginal microspheres containing Terbinafine (TBH) in order to provide long-term therapeutic activity at the site of infection and prove the same using in vitro anti fungal activity of the same using Candida albicans. Microspheres were prepared by the Solvent extraction technique using sodium hyaluronate and Arlacel A. Microspheres were characterized by SEM, DSC, FTIR, particle size analysis and evaluated for percentage yield, drug loading, encapsulation efficiency and in vitro drug release. FTIR and DSC studies showed that no chemical changes or alterations occurred in the drug and polymers. The sphericity factor indicated that the prepared microspheres were spherical. Formulation (TBHMs) indicated a controlled in vitro drug release and good bioadhesive strength. The in vitro anti fungal activity confirmed for a controlled and prolonged capacity of the prepared novel formulation. The results indicated that this drug delivery system can be explored for controlled intra-vaginal drug release.
Original language | English |
---|---|
Pages (from-to) | 4767-4776 |
Number of pages | 10 |
Journal | International Journal of Pharmaceutical Sciences and Research |
Volume | 8 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 2017 |
Keywords
- Vaginal yeast infection
- Terbinafine (TBH)
- Microspheres
- Hyaluronic acid
- Novel formulation
- Terbinafine microspheres (TBHMs)